SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

Search

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

62.95 1.04

Rezumat

Modificarea prețului

24h

Curent

Minim

62.2

Maxim

62.9

Indicatori cheie

By Trading Economics

Venit

49M

76M

Vânzări

51M

210M

P/E

Medie Sector

26.54

76.798

EPS

1.135

Randament dividend

1.5

Marjă de profit

35.965

Angajați

2,197

EBITDA

49M

84M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+44.93% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.50%

2.37%

Statistici piață

By TradingEconomics

Capitalizare de piață

-18M

3.2B

Deschiderea anterioară

61.91

Închiderea anterioară

62.95

Sentimentul știrilor

By Acuity

50%

50%

166 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 dec. 2025, 23:54 UTC

Principalele dinamici ale pieței

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec. 2025, 19:08 UTC

Achiziții, Fuziuni, Preluări

Correction to Alphabet to Buy Intersect Article

22 dec. 2025, 17:21 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec. 2025, 16:46 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec. 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec. 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec. 2025, 22:31 UTC

Câștiguri

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec. 2025, 22:31 UTC

Câștiguri

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec. 2025, 22:30 UTC

Câștiguri

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 dec. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22 dec. 2025, 21:37 UTC

Achiziții, Fuziuni, Preluări

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec. 2025, 20:54 UTC

Achiziții, Fuziuni, Preluări

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec. 2025, 20:52 UTC

Achiziții, Fuziuni, Preluări

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec. 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec. 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec. 2025, 19:49 UTC

Achiziții, Fuziuni, Preluări

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec. 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec. 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 dec. 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22 dec. 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22 dec. 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec. 2025, 18:30 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec. 2025, 18:23 UTC

Achiziții, Fuziuni, Preluări

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22 dec. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 dec. 2025, 17:06 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

44.93% sus

Prognoză pe 12 luni

Medie 90 EUR  44.93%

Maxim 90 EUR

Minim 90 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

166 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat